Browse by UCL people
Group by: Type | Date
Jump to: Article | Conference item
Number of items: 136.
Article
Ainley, L;
Chavda, SJ;
Counsell, N;
Cheesman, S;
Newrick, F;
Horder, J;
Kyriakou, C;
... Yong, K; + view all
(2021)
DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
British Journal of Haematology
, 192
(3)
e73-e77.
10.1111/bjh.17248.
|
Alaggio, Rita;
Amador, Catalina;
Anagnostopoulos, Ioannis;
Attygalle, Ayoma D;
Araujo, Iguaracyra Barreto de Oliveira;
Berti, Emilio;
Bhagat, Govind;
... Xiao, Wenbin; + view all
(2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
Leukemia
10.1038/s41375-022-01620-2.
(In press).
|
Asher, Samir;
Kazantzi, Aikaterini;
Dekaj, Fatjon;
Steventon, Luke;
Khatun, Aisha;
Ainley, Louise;
McMillan, Annabel;
... Popat, Rakesh; + view all
(2022)
Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma.
Haematologica
, 107
(12)
pp. 2961-2965.
10.3324/haematol.2022.281322.
|
Baggiano, A;
Boldrini, M;
Martinez-Naharro, A;
Kotecha, T;
Petrie, A;
Rezk, T;
Gritti, M;
... Fontana, M; + view all
(2020)
Noncontrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis.
JACC: Cardiovascular Imaging
, 13
(1(1))
pp. 69-80.
10.1016/j.jcmg.2019.03.026.
|
Banypersad, SM;
Fontana, M;
Maestrini, V;
Sado, DM;
Captur, G;
Petrie, A;
Piechnik, SK;
... Moon, JC; + view all
(2015)
T1 mapping and survival in systemic light-chain amyloidosis.
Eur Heart J
, 36
(4)
244 - 251.
10.1093/eurheartj/ehu444.
|
Bomsztyk, Joshua;
Khwaja, Jahanzaib;
Wechalekar, Ashutosh D;
(2022)
Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner's perspective.
Expert Review of Hematology
10.1080/17474086.2022.2115353.
(In press).
|
Bomsztyk, Joshua;
Ravichandran, Sriram;
Giles, Hannah Victoria;
Wright, Nicola Jane;
Berlanga, Oscar;
Khwaja, Jahanzaib;
Mahmood, Shameem;
... Wechalekar, Ashutosh D; + view all
(2024)
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
Blood
, 143
(13)
pp. 1259-1268.
10.1182/blood.2023022399.
|
Boyle, EM;
Ashby, C;
Wardell, CP;
Rowczenio, D;
Sachchithanantham, S;
Wang, Y;
Johnson, SK;
... Wechalekar, AD; + view all
(2018)
The genomic landscape of plasma cells in systemic light chain amyloidosis.
Blood
, 132
(26)
pp. 2775-2777.
10.1182/blood-2018-08-872226.
|
Carr, AS;
Shah, S;
Choi, D;
Blake, J;
Phadke, R;
Gilbertson, J;
Whelan, CJ;
... Reilly, MM; + view all
(2019)
Spinal Stenosis in Familial Transthyretin Amyloidosis.
Journal of Neuromuscular Diseases
10.3233/JND-180348.
(In press).
|
Chacko, L;
Boldrini, M;
Martone, R;
Law, S;
Martinez-Naharrro, A;
Hutt, DF;
Kotecha, T;
... Fontana, M; + view all
(2021)
Cardiac Magnetic Resonance–Derived Extracellular Volume Mapping for the Quantification of Hepatic and Splenic Amyloid.
Circulation: Cardiovascular Imaging
, 14
(4)
, Article e012506. 10.1161/CIRCIMAGING.121.012506.
|
Chacko, L;
Martone, R;
Bandera, F;
Lane, T;
Martinez-Naharro, A;
Boldrini, M;
Rezk, T;
... Fontana, M; + view all
(2020)
Echocardiographic phenotype and prognosis in transthyretin cardiac amyloidosis.
European Heart Journal
, 41
(14)
pp. 1439-1447.
10.1093/eurheartj/ehz905.
|
Chavda, SJ;
Pocock, R;
Cheesman, S;
Lee, K-M;
Dowling, E;
Marks, DJB;
Kyriakou, C;
... Popat, R; + view all
(2020)
Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.
British Journal of Haematology
10.1111/bjh.16889.
(In press).
|
Cheng, Richard;
Kittleson, Michelle M;
Wechalekar, Ashutosh D;
Alvarez-Cardona, Jose;
Mitchell, Joshua D;
Macedo, Ariane Vieira Scarlatelli;
Dutra, Joao Pedro Passos;
... Lenihan, Daniel; + view all
(2024)
Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statement.
Heart
10.1136/heartjnl-2023-323502.
(In press).
|
Cohen, Oliver;
Rendas-Baum, Regina;
McCausland, Kristen;
Foard, Darren;
Manwani, Richa;
Ravichandran, Sriram;
Lachmann, Helen;
... Wechalekar, Ashutosh; + view all
(2023)
Linking changes in quality of life to haematologic response and survival in systemic immunoglobulin light-chain amyloidosis.
British Journal of Haematology
, 201
(3)
pp. 422-431.
10.1111/bjh.18645.
|
Cohen, Oliver C;
Ismael, Andreia;
Pawarova, Babita;
Manwani, Richa;
Ravichandran, Sriram;
Law, Steven;
Foard, Darren;
... Wechalekar, Ashutosh D; + view all
(2022)
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis.
European Heart Journal
, 43
(4)
pp. 333-341.
10.1093/eurheartj/ehab507.
|
Cohen, Oliver C;
Sathyanath, Ananth;
Petrie, Aviva;
Ravichandran, Sriram;
Law, Steven;
Manwani, Richa;
Foard, Darren;
... Wechalekar, Ashutosh D; + view all
(2022)
Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis.
Heart
, 108
(20)
pp. 1616-1622.
10.1136/heartjnl-2021-320703.
|
Cohen, OC;
Brodermann, MH;
Blakeney, IJ;
Mahmood, S;
Sachchithanantham, S;
Ravichandran, S;
Law, S;
... Wechalekar, AD; + view all
(2020)
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Amyloid
, 27
(3)
pp. 200-205.
10.1080/13506129.2020.1765768.
|
Cohen, OC;
Law, S;
Lachmann, HJ;
Sharpley, F;
Ravichandran, S;
Mahmood, S;
Sachchithanantham, S;
... Wechalekar, AD; + view all
(2020)
The impact and importance of achieving a complete haematological response prior to renal transplantation in AL amyloidosis.
Blood Cancer Journal
, 10
(5)
, Article 60. 10.1038/s41408-020-0325-2.
|
Cohen, OC;
Sharpley, F;
Gilbertson, JA;
Wechalekar, AD;
Sachchithanantham, S;
Mahmood, S;
Whelan, CJ;
... Gillmore, JD; + view all
(2020)
The value of screening biopsies in light chain (AL) and transthyretin (ATTR) amyloidosis.
European Journal of Haematology
, 105
(3)
pp. 352-356.
10.1111/ejh.13458.
|
Cohen, OC;
Sharpley, F;
Gillmore, JD;
Lachmann, HJ;
Sachchithanantham, S;
Mahmood, S;
Fontana, M;
... Wechalekar, AD; + view all
(2020)
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis.
British Journal of Haematology
, 189
(4)
pp. 643-649.
10.1111/bjh.16401.
|
Cohen, OC;
Wechalekar, AD;
(2020)
Systemic amyloidosis: moving into the spotlight.
Leukemia
, 34
(5)
pp. 1215-1228.
10.1038/s41375-020-0802-4.
|
da Silva Filho, MI;
Försti, A;
Weinhold, N;
Meziane, I;
Campo, C;
Huhn, S;
Nickel, J;
... Hemminki, K; + view all
(2017)
Genome-wide association study of immunoglobulin light chain amyloidosis in three patient cohorts: comparison with myeloma.
Leukemia
, 31
(8)
pp. 1735-1742.
10.1038/leu.2016.387.
|
Dispenzieri, A;
Kastritis, E;
Wechalekar, AD;
Schönland, SO;
Kim, K;
Sanchorawala, V;
Landau, HJ;
... Merlini, G; + view all
(2021)
A randomized phase 3 study of ixazomib–dexamethasone versus physician’s choice in relapsed or refractory AL amyloidosis.
Leukemia
10.1038/s41375-021-01317-y.
(In press).
|
Fontana, M;
Pica, S;
Reant, P;
Abdel-Gadir, A;
Treibel, TA;
Banypersad, SM;
Maestrini, V;
... Moon, JC; + view all
(2015)
Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.
Circulation
, 132
(16)
pp. 1570-1579.
10.1161/CIRCULATIONAHA.115.016567.
|
Fox, TA;
Lunn, M;
Wechalekar, A;
Bomanji, J;
Wan, S;
D'Sa, S;
(2018)
[18F]Florbetaben PET-CT confirms AL amyloidosis in a patient with Waldenström's Macroglobulinaemia.
Haematologica
, 103
(6)
10.3324/haematol.2017.184515.
|
Gertz, MA;
Cohen, AD;
Comenzo, RL;
Kastritis, E;
Landau, HJ;
Libby, EN;
Liedtke, M;
... Merlini, G; + view all
(2023)
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Blood
10.1182/blood.2022019406.
(In press).
|
Ghinai, RAM;
Mahmood, S;
Mukonoweshuro, P;
Webber, S;
Wechalekar, AD;
Moore, SE;
(2017)
Diagnosing Light Chain Amyloidosis on Temporal Artery Biopsies for Suspected Giant Cell Arteritis.
Journal of Neuro-Ophthalmology
, 37
(1)
pp. 34-39.
10.1097/WNO.0000000000000447.
|
Gillmore, JD;
Maurer, MS;
Falk, RH;
Merlini, G;
Damy, T;
Dispenzieri, A;
Wechalekar, AD;
... Hawkins, PN; + view all
(2016)
Non-Biopsy Diagnosis of Cardiac Transthyretin Amyloidosis.
Circulation
, 133
(24)
pp. 2404-2412.
10.1161/CIRCULATIONAHA.116.021612.
|
Havasi, Andrea;
Heybeli, Cihan;
Leung, Nelson;
Angel-Korman, Avital;
Sanchorawala, Vaishali;
Cohen, Oliver;
Wechalekar, Ashutosh;
... Landau, Heather; + view all
(2022)
Outcomes of renal transplantation in patients with AL amyloidosis: an international collaboration through The International Kidney and Monoclonal Gammopathy Research Group.
Blood Cancer Journal
, 12
(8)
, Article 119. 10.1038/s41408-022-00714-5.
|
Hutt, DF;
Fontana, M;
Burniston, M;
Quigley, AM;
Petrie, A;
Ross, JC;
Page, J;
... Gillmore, JD; + view all
(2017)
Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.
European Heart Journal - Cardiovascular Imaging
, 18
(12)
pp. 1344-1350.
10.1093/ehjci/jew325.
|
Inaugural Amyloidosis Forum Panelists, .;
Lousada, I;
(2020)
The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis.
Orphanet Journal of Rare Diseases
, 15
(1)
, Article 268. 10.1186/s13023-020-01525-2.
|
|
Jamroziak, Krzysztof;
Zielonka, Klaudia;
Khwaja, Jahanzaib;
Wechalekar, Ashutosh D;
(2025)
Update on B-cell maturation antigen-directed therapies in AL amyloidosis.
British Journal of Haematology
, 206
(3)
pp. 817-831.
10.1111/bjh.19960.
|
Kastritis, E;
Palladini, G;
Minnema, MC;
Wechalekar, AD;
Jaccard, A;
Lee, HC;
Sanchorawala, V;
... ANDROMEDA Trial Investigators, .; + view all
(2021)
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
New England Journal of Medicine
, 385
(1)
pp. 46-58.
10.1056/NEJMoa2028631.
|
Kastritis, Efstathios;
Misra, Arpit;
Gurskyte, Laura;
Kroi, Florint;
Verhoek, Andre;
Vermeulen, Jessica;
Ammann, Eric;
... Wechalekar, Ashutosh D; + view all
(2023)
Assessing the prognostic utility of hematologic response for overall survival in patients with newly diagnosed AL amyloidosis: results of a meta-analysis.
Hematology
, 28
(1)
, Article 2157581. 10.1080/16078454.2022.2157581.
|
Kastritis, E;
Leleu, X;
Arnulf, B;
Zamagni, E;
Cibeira, MT;
Kwok, F;
Mollee, P;
... Palladini, G; + view all
(2020)
Bortezomib, Melphalan, and Dexamethasone for Light-Chain Amyloidosis.
Journal of Clinical Oncology
, 38
(28)
pp. 3252-3260.
10.1200/JCO.20.01285.
|
Kastritis, E;
Wechalekar, A;
Schoenland, S;
Sanchorawala, V;
Merlini, G;
Palladini, G;
Minnema, M;
... Dimopoulos, MA; + view all
(2020)
Challenges in the management of patients with systemic light chain (AL) amyloidosis during the COVID-19 pandemic.
British Journal of Haematology
, 190
(3)
pp. 346-357.
10.1111/bjh.16898.
|
Khwaja, J;
D'Sa, S;
Minnema, MC;
Kersten, MJ;
Wechalekar, A;
Vos, JM;
(2022)
IgM monoclonal gammopathies of clinical significance: diagnosis and management.
Haematologica
, 107
(9)
pp. 2037-2050.
10.3324/haematol.2022.280953.
|
Khwaja, Jahanzaib;
Bomsztyk, Joshua;
Atta, Maria;
Bygrave, Ceri;
Forbes, Adam;
Durairaj, Senthil;
Fernandes, Savio;
... Wechalekar, Ashutosh D; + view all
(2024)
Real-world efficacy of single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
British Journal of Haematology
, 204
(5)
pp. 1811-1815.
10.1111/bjh.19286.
|
Khwaja, Jahanzaib;
Bomsztyk, Joshua;
Mahmood, Shameem;
Wisniowski, Brendan;
Shah, Raakhee;
Tailor, Anish;
Yong, Kwee;
... Wechalekar, Ashutosh D; + view all
(2022)
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Blood Cancer Journal
, 12
(9)
, Article 128. 10.1038/s41408-022-00717-2.
|
Khwaja, Jahanzaib;
Vos, Josephine MI;
Pluimers, Tessa E;
Japzon, Nicole;
Patel, Aisha;
Salter, Simon;
Kwakernaak, Arjan J;
... D'Sa, Shirley; + view all
(2024)
Clinical and clonal characteristics of monoclonal immunoglobulin M-associated type I cryoglobulinaemia.
British Journal of Haematology
, 204
(1)
pp. 177-185.
10.1111/bjh.19112.
|
Knight, DS;
Zumbo, G;
Barcella, W;
Steeden, JA;
Muthurangu, V;
Martinez-Naharro, A;
Treibel, TA;
... Fontana, M; + view all
(2019)
Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles.
JACC Cardiovascular Imaging
, 12
(5)
pp. 823-833.
10.1016/j.jcmg.2018.02.016.
|
Kotecha, T;
Martinez-Naharro, A;
Treibel, TA;
Francis, R;
Nordin, S;
Abdel-Gadir, A;
Knight, DS;
... Fontana, M; + view all
(2018)
Myocardial Edema and Prognosis in Amyloidosis.
Journal of the American College of Cardiology
, 71
(25)
pp. 2919-2931.
10.1016/j.jacc.2018.03.536.
|
Lane, T;
Fontana, M;
Martinez-Naharro, A;
Quarta, CC;
Whelan, CJ;
Petrie, A;
Rowczenio, DM;
... Gillmore, JD; + view all
(2019)
Natural History, Quality of Life, and Outcome in Cardiac Transthyretin Amyloidosis.
Circulation
, 140
(1)
pp. 16-26.
10.1161/CIRCULATIONAHA.118.038169.
|
Lane, T;
Pinney, JH;
Gilbertson, JA;
Hutt, DF;
Rowczenio, DM;
Mahmood, S;
Sachchithanantham, S;
... Lachmann, HJ; + view all
(2017)
Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre.
Amyloid: The Journal of Protein Folding Disorders
, 24
(3)
pp. 162-166.
10.1080/13506129.2017.1342235.
|
Lane, T;
Rowczenio, DM;
Gilbertson, JA;
Gillmore, JD;
Wechalekar, AD;
Hawkins, PN;
Lachmann, HJ;
(2015)
Empirical use of anakinra in AA amyloidosis of uncertain aetiology.
Pediatric Rheumatology
, 13
(Supp 1)
, Article O70. 10.1186/1546-0096-13-S1-O70.
|
Lane, T;
Wechalekar, AD;
Gillmore, JD;
Hawkins, PN;
Lachmann, HJ;
(2017)
Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology.
Amyloid
, 24
(3)
pp. 189-193.
10.1080/13506129.2017.1352503.
|
Law, S;
Cohen, O;
Lachmann, H;
Rezk, T;
Gilbertson, J;
Rowczenio, D;
Wechalekar, A;
... Gillmore, J; + view all
(2021)
Renal Transplant Outcomes in Amyloidosis.
Nephrology Dialysis Transplantation
, 36
(2)
pp. 355-365.
10.1093/ndt/gfaa293.
|
Law, S;
Petrie, A;
Chacko, L;
Cohen, OC;
Ravichandran, S;
Gilbertson, JA;
Rowczenio, D;
... Gillmore, JD; + view all
(2020)
Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage.
ESC Heart Failure
10.1002/ehf2.12989.
(In press).
|
Law, S;
Petrie, A;
Chacko, L;
Cohen, OC;
Ravichandran, S;
Gilbertson, JA;
Rowczenio, D;
... Gillmore, JD; + view all
(2021)
Change in N-terminal pro-B-type natriuretic peptide at 1 year predicts mortality in wild-type transthyretin amyloid cardiomyopathy.
Heart
10.1136/heartjnl-2021-319063.
(In press).
|
Leblond, V;
Kastritis, E;
Advani, R;
Ansell, SM;
Buske, C;
Castillo, JJ;
Garcia-Sanz, R;
... Dimopoulos, MA; + view all
(2016)
Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia.
Blood
, 128
(10)
pp. 1321-1328.
10.1182/blood-2016-04-711234.
|
Lecat, CSY;
Taube, JBB;
Wilson, W;
Carmichael, J;
Parrish, C;
Wallis, G;
Kyriakou, C;
... Popat, R; + view all
(2021)
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma.
Frontiers in Oncology
, 11
, Article 703233. 10.3389/fonc.2021.703233.
|
Leung, N;
Bridoux, F;
Batuman, V;
Chaidos, A;
Cockwell, P;
D'Agati, VD;
Dispenzieri, A;
... Nasr, SH; + view all
(2019)
The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.
Nature Reviews Nephrology
, 15
(1)
pp. 45-59.
10.1038/s41581-018-0077-4.
|
Luo, MM;
Zhu, PP;
Nnane, I;
Xiong, Y;
Merlini, G;
Comenzo, RL;
Kastritis, E;
... Zhou, H; + view all
(2022)
Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis.
The Journal of Clinical Pharmacology
, 62
(5)
pp. 656-669.
10.1002/jcph.1994.
|
Maciocia, N;
Wechalekar, A;
Yong, K;
(2016)
Monoclonal gammopathy of undetermined significance and smoldering myeloma (SMM): a practical guide to management.
Hematological Oncology
, 35
(4)
pp. 432-439.
10.1002/hon.2345.
|
Mahmood, S;
Sovani, M;
Smith, P;
George, L;
Quarta, CC;
Sachchithanantham, S;
Fontana, M;
... Wechalekar, AD; + view all
(2017)
High prevalence of recurrent nocturnal desaturations in systemic AL amyloidosis: a cross-sectional pilot study.
[Review].
Sleep Medicine
, 32
pp. 191-197.
10.1016/j.sleep.2016.11.021.
|
Mahmood, S;
Wassef, NL;
Salter, SJ;
Sachchithanantham, S;
Lane, T;
Foard, D;
Whelan, CJ;
... Wechalekar, AD; + view all
(2016)
Comparison of Free Light Chain Assays Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis.
American Journal of Clinical Pathology
, 146
(1)
pp. 78-85.
10.1093/ajcp/aqw079.
|
Manwani, R;
Cohen, O;
Sharpley, F;
Mahmood, S;
Sachchithanantham, S;
Foard, D;
Lachmann, HJ;
... Wechalekar, AD; + view all
(2019)
A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib.
Blood
, 134
(25)
pp. 2271-2280.
10.1182/blood.2019000834.
|
Manwani, R;
Foard, D;
Mahmood, S;
Sachchithanantham, S;
Lane, T;
Quarta, C;
Youngstein, T;
... Wechalekar, AD; + view all
(2018)
Rapid Hematologic Responses Improve Outcomes In Patients With Very Advanced (Stage IIIb) Cardiac Immunoglobulin Light Chain Amyloidosis.
Haematologica
, 103
(4)
e165-e168.
10.3324/haematol.2017.178095.
|
Manwani, R;
Hegenbart, U;
Mahmood, S;
Sachchithanantham, S;
Kyriakou, C;
Yong, K;
Popat, R;
... Wechalekar, A; + view all
(2018)
Deferred autologous stem cell transplantation in systemic AL amyloidosis.
Blood Cancer Journal
, 8
, Article 101. 10.1038/s41408-018-0137-9.
|
Manwani, R;
Mahmood, S;
Sachchithanantham, S;
Lachmann, HJ;
Gillmore, JD;
Yong, K;
Rabin, N;
... Wechalekar, AD; + view all
(2019)
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
British Journal of Haematology
, 187
(5)
pp. 638-641.
10.1111/bjh.16122.
|
Manwani, R;
Page, J;
Lane, T;
Burniston, M;
Skillen, A;
Lachmann, HJ;
Gillmore, JD;
... Wechalekar, AD; + view all
(2018)
A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement.
Amyloid. The Journal of Protein Folding Disorders
, 25
(4)
pp. 247-252.
10.1080/13506129.2018.1552852.
|
Manwani, R;
Sachchithanantham, S;
Mahmood, S;
Foard, D;
Sharpley, F;
Rezk, T;
Lane, T;
... Wechalekar, AD; + view all
(2018)
Treatment of IgM-associated immunoglobulin light chain amyloidosis with Rituximab-Bendamustine.
Blood
10.1182/blood-2018-04-846493.
(In press).
|
Manwani, R;
Wrench, D;
Wechalekar, A;
Lachmann, H;
(2018)
Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma.
British Journal of Haematology
, 182
(5)
p. 619.
10.1111/bjh.15269.
|
Martinez-Naharro, Ana;
Patel, Rishi;
Kotecha, Tushar;
Karia, Nina;
Ioannou, Adam;
Petrie, Aviva;
Chacko, Liza A;
... Fontana, Marianna; + view all
(2022)
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment.
European Heart Journal
, 43
pp. 4722-4735.
10.1093/eurheartj/ehac363.
|
Martinez-Naharro, A;
Abdel-Gadir, A;
Treibel, TA;
Zumbo, G;
Knight, DS;
Rosmini, S;
Lane, T;
... Fontana, M; + view all
(2018)
CMR-Verified Regression of Cardiac AL Amyloid After Chemotherapy.
[Letter].
JACC: Cardiovascular Imaging
, 11
(1)
pp. 152-154.
10.1016/j.jcmg.2017.02.012.
|
Merlini, G;
Lousada, I;
Ando, Y;
Dispenzieri, A;
Gertz, MA;
Grogan, M;
Maurer, MS;
... Comenzo, RL; + view all
(2016)
Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis.
Leukemia
, 30
(10)
pp. 1979-1986.
10.1038/leu.2016.191.
|
Meziane, I;
Huhn, S;
da Silva Filho, MI;
Weinhold, N;
Campo, C;
Nickel, J;
Hoffmann, P;
... Hemminki, K; + view all
(2017)
Genome-wide association study of clinical parameters in immunoglobulin light chain amyloidosis in three patient cohorts.
[Letter].
Haematologica
, 102
(10)
e411-e414.
10.3324/haematol.2017.171108.
|
Milani, P;
Sharpley, F;
Schoenland, SO;
Basset, M;
Mahmood, S;
Nuvolone, M;
Kimmich, C;
... Hegenbart, U; + view all
(2020)
Pomalidomide and dexamethasone grant rapid haematologic responses in patients with relapsed and refractory AL amyloidosis: a European retrospective series of 153 patients.
The Journal of Protein Folding Disorders
, 27
(4)
pp. 231-236.
10.1080/13506129.2020.1767566.
|
Minnema, MC;
Dispenzieri, A;
Merlini, G;
Comenzo, RL;
Kastritis, E;
Wechalekar, AD;
Grogan, M;
... Jaccard, A; + view all
(2022)
Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial.
JACC: CardioOncology
, 4
(4)
pp. 474-487.
10.1016/j.jaccao.2022.08.011.
|
Muchtar, Eli;
Dispenzieri, Angela;
Wisniowski, Brendan;
Palladini, Giovanni;
Milani, Paolo;
Merlini, Giampaolo;
Schönland, Stefan;
... Gertz, Morie A; + view all
(2023)
Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis.
Journal of Clinical Oncology
, 41
(7)
pp. 1393-1403.
10.1200/JCO.22.00643.
|
Muchtar, Eli;
Wisniowski, Brendan;
Geyer, Susan;
Palladini, Giovanni;
Milani, Paolo;
Merlini, Giampaolo;
Schönland, Stefan;
... Gertz, Morie A; + view all
(2024)
Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.
JAMA oncology
, 10
(10)
pp. 1362-1369.
10.1001/jamaoncol.2024.2629.
|
Nesr, George;
Shah, Raakhee;
Kyriakou, Charalampia;
Sive, Jonathan;
Popat, Rakesh;
Yong, Kwee;
Wisniowski, Brendan;
... Rabin, Neil; + view all
(2023)
Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience.
Leukemia & Lymphoma
10.1080/10428194.2023.2216817.
(In press).
|
Nyktari, E;
Vassiliou, VS;
Arzanauskaite, M;
Gatehouse, P;
Greiser, A;
Wechalekar, A;
Gilbertson, J;
... Mohiaddin, R; + view all
(2017)
Challenging Occam's Razor: An Unusual Combination of Sarcoidosis and Amyloidosis. The Value of Cardiac Magnetic Resonance Imaging in Infiltrative Cardiomyopathies.
Canadian Journal of Cardiology
, 33
(10)
1335.e9-1335.e11.
10.1016/j.cjca.2017.07.004.
|
Palladini, Giovanni;
Schönland, Stefan;
Merlini, Giampaolo;
Milani, Paolo;
Jaccard, Arnaud;
Bridoux, Frank;
Dimopoulos, Meletios A;
... Wechalekar, Ashutosh; + view all
(2023)
The management of light chain (AL) amyloidosis in Europe: clinical characteristics, treatment patterns, and efficacy outcomes between 2004 and 2018.
Blood Cancer Journal
, 13
(1)
, Article 19. 10.1038/s41408-023-00789-8.
|
Palladini, G;
Kastritis, E;
Maurer, MS;
Zonder, JA;
Minnema, MC;
Wechalekar, AD;
Jaccard, A;
... Comenzo, RL; + view all
(2020)
Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA.
Blood
, 136
(1)
pp. 71-80.
10.1182/blood.2019004460.
|
Palladini, G;
Paiva, B;
Wechalekar, A;
Massa, M;
Milani, P;
Lasa, M;
Ravichandran, S;
... Merlini, G; + view all
(2021)
Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.
Blood Cancer Journal
, 11
, Article 34. 10.1038/s41408-021-00428-0.
|
Papa, R;
Gilbertson, JA;
Rendell, N;
Wechalekar, AD;
Gillmore, JD;
Hawkins, PN;
Lachmann, HJ;
(2020)
Two types of systemic amyloidosis in a single patient.
Amyloid
, 27
(4)
pp. 275-276.
10.1080/13506129.2020.1760238.
|
Patel, Rishi K;
Bandera, Francesco;
Venneri, Lucia;
Porcari, Aldostefano;
Razvi, Yousuf;
Ioannou, Adam;
Chacko, Liza;
... Fontana, Marianna; + view all
(2024)
Cardiopulmonary Exercise Testing in Evaluating Transthyretin Amyloidosis.
JAMA Cardiology
, 9
(4)
pp. 367-376.
10.1001/jamacardio.2024.0022.
|
Phillips, EH;
Nash, S;
Adedayo, T;
Whelan, CJ;
Fontana, M;
Mahmood, S;
Lachmann, HJ;
... Wechalekar, AD; + view all
(2017)
Pitfalls in conducting prospective trials in stage III cardiac amyloidosis - experience from the REVEAL study.
Amyloid
, 24
(4)
pp. 250-252.
10.1080/13506129.2017.1385453.
|
Pinney, JH;
Smith, CJ;
Taube, JB;
Lachmann, HJ;
Venner, CP;
Gibbs, SD;
Dungu, J;
... Gillmore, JD; + view all
(2013)
Systemic amyloidosis in England: an epidemiological study.
Br J Haematol
, 161
(4)
525 - 532.
10.1111/bjh.12286.
|
Premkumar, VJ;
Lentzsch, S;
Pan, S;
Bhutani, D;
Richter, J;
Jagannath, S;
Liedtke, M;
... Kapoor, P; + view all
(2021)
Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.
Blood Cancer Journal
, 11
(1)
, Article 10. 10.1038/s41408-020-00397-w.
|
Quarta, CC;
Gonzalez-Lopez, E;
Gilbertson, JA;
Botcher, N;
Rowczenio, D;
Petrie, A;
Rezk, T;
... Gillmore, JD; + view all
(2017)
Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis.
European Heart Journal
, 38
(24)
pp. 1905-1908.
10.1093/eurheartj/ehx047.
|
Quarta, CC;
Zheng, J;
Hutt, D;
Grigore, SF;
Manwani, R;
Sachchithanantham, S;
Mahmood, SA;
... Wechalekar, AD; + view all
(2021)
99mTc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis.
European Heart Journal - Cardiovascular Imaging
10.1093/ehjci/jeab095.
(In press).
|
Ravichandran, S;
Cohen, OC;
Law, S;
Sachchithanantham, S;
Mahmood, S;
Foard, D;
Fontana, M;
... Wechalekar, AD; + view all
(2021)
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data.
British Journal of Haematology
, 194
(3)
pp. 587-597.
10.1111/bjh.17636.
|
Ravichandran, Sriram;
Hall, Andrew;
Jenner, Matthew;
Garg, Mamta;
Kishore, Bhuvan;
Lachmann, Helen;
Gillmore, Julian;
... Wechalekar, Ashutosh; + view all
(2023)
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.
Amyloid
, 30
(3)
pp. 1-7.
10.1080/13506129.2023.2169124.
|
Ravichandran, Sriram;
Law, Steven;
Mahmood, Shameem;
Wisniowski, Brenden;
Foard, Darren;
Fontana, Marianna;
Martinez-Naharro, Ana;
... Wechalekar, Ashutosh D; + view all
(2022)
Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis.
Leukemia
10.1038/s41375-021-01497-7.
(In press).
|
Ravichandran, Sriram;
Law, Steven;
Mahmood, Shameem;
Wisniowski, Brenden;
Foard, Darren;
Fontana, Marianna;
Martinez-Naharro, Ana;
... Wechalekar, Ashutosh D; + view all
(2022)
Long-term outcomes in light chain deposition disease- analysis of a UK cohort.
American Journal of Hematology
, 97
(12)
E444-E446.
10.1002/ajh.26725.
|
Ravichandran, Sriram;
Mahmood, Shameem;
Wisniowski, Brenden;
Sachchithanantham, Sajitha;
Popat, Rakesh;
Lachmann, Helen;
Rabin, Neil;
... D Wechalekar, Ashutosh; + view all
(2022)
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosis.
British Journal of Haematology
, 198
(2)
pp. 328-332.
10.1111/bjh.18216.
|
Ravichandran, S;
Cohen, OC;
Law, S;
Foard, D;
Fontana, M;
Martinez-Naharro, A;
Whelan, C;
... Wechalekar, AD; + view all
(2021)
Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib.
Blood Cancer Journal
, 11
(6)
, Article 118. 10.1038/s41408-021-00510-7.
|
Ravichandran, S;
Lachmann, HJ;
Wechalekar, AD;
(2020)
Epidemiologic and Survival Trends in Amyloidosis, 1987–2019.
The New England Journal of Medicine
, 382
(16)
pp. 1567-1568.
10.1056/NEJMc1917321.
|
Rezk, T;
Davenport, A;
Gan, JJ;
Lachmann, HJ;
Fontana, M;
Martinez-Naharro, A;
Sachchithanantham, S;
... Gillmore, JD; + view all
(2019)
Bioimpedance vector analysis for the detection of extracellular volume overload and sarcopenia in systemic AL amyloidosis.
British Journal of Haematology
, 185
(5)
pp. 977-980.
10.1111/bjh.15675.
|
Rezk, T;
Gilbertson, JA;
Mangione, PP;
Rowczenio, D;
Rendell, N;
Canetti, D;
Lachmann, HJ;
... Gillmore, JD; + view all
(2019)
The complementary role of histology and proteomics for diagnosis and typing of systemic amyloidosis.
Journal of Pathology: Clinical Research
, 5
(3)
pp. 145-153.
10.1002/cjp2.126.
|
Rezk, T;
Gilbertson, JA;
Rowczenio, D;
Bass, P;
Lachmann, HJ;
Wechalekar, AD;
Fontana, M;
... Gillmore, JD; + view all
(2018)
Diagnosis, pathogenesis and outcome in leucocyte chemotactic factor 2 (ALECT2) amyloidosis.
Nephrology Dialysis Transplantation
, 33
(2)
pp. 241-247.
10.1093/ndt/gfw375.
|
Rezk, T;
Lachmann, HJ;
Fontana, M;
Naharro, AM;
Sachchithanantham, S;
Mahmood, S;
Petrie, A;
... Gillmore, JD; + view all
(2019)
Cardiorenal AL amyloidosis: risk stratification and outcomes based upon cardiac and renal biomarkers.
British Journal of Haematology
, 186
(3)
pp. 460-470.
10.1111/bjh.15955.
|
Rezk, T;
Lachmann, HJ;
Fontana, M;
Sachchithanantham, S;
Mahmood, S;
Petrie, A;
Whelan, CJ;
... Gillmore, JD; + view all
(2017)
Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor.
Kidney International
, 92
(6)
pp. 1476-1483.
10.1016/j.kint.2017.05.004.
|
Rezk, T;
Salota, R;
Gan, JJ;
Lachmann, HJ;
Fontana, M;
Siew, K;
Martinez-Naharro, A;
... Gillmore, JD; + view all
(2021)
Urinary retinol binding protein predicts renal outcome in systemic immunoglobulin light-chain (AL) amyloidosis.
British Journal of Haematology
10.1111/bjh.17706.
|
Rezk, T;
Whelan, CJ;
Lachmann, HJ;
Fontana, M;
Sachchithanantham, S;
Mahmood, S;
Khan, F;
... Wechalekar, AD; + view all
(2017)
Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis.
[Letter].
British Journal of Haematology
10.1111/bjh.14747.
(In press).
|
Richards, DB;
Cookson, LM;
Barton, SV;
Liefaard, L;
Lane, T;
Hutt, DF;
Ritter, JM;
... Pepys, MB; + view all
(2018)
Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
Science Translational Medecine
, 10
(422)
, Article eaan3128. 10.1126/scitranslmed.aan3128.
|
Ross, JC;
Hutt, DF;
Burniston, M;
Page, J;
Steeden, JA;
Gillmore, JD;
Wechalekar, AD;
... Fontana, M; + view all
(2018)
Quantitation of Tc-99m-DPD uptake in patients with transthyretin-related cardiac amyloidosis.
Amyloid
, 25
(3)
pp. 203-210.
10.1080/13506129.2018.1520087.
|
Rowczenio, D;
Quarta, CC;
Fontana, M;
Whelan, CJ;
Martinez-Naharro, A;
Trojer, H;
Baginska, A;
... Lachmann, HJ; + view all
(2019)
Analysis of the TTR gene in the investigation of amyloidosis: A 25 year single UK centre experience.
Human Mutation
, 40
(1)
pp. 90-96.
10.1002/humu.23669.
|
Rowczenio, D;
Stensland, M;
de Souza, GA;
Strøm, EH;
Gilbertson, JA;
Taylor, G;
Rendell, N;
... Wien, TN; + view all
(2017)
Renal Amyloidosis Associated With 5 Novel Variants in the Fibrinogen A Alpha Chain Protein.
Kidney International Reports
, 2
(3)
pp. 461-469.
10.1016/j.ekir.2016.11.005.
|
Rowczenio, DM;
Pathak, S;
Arostegui, JI;
Mensa-Vilaro, A;
Omoyinmi, E;
Brogan, P;
Lipsker, D;
... Lachmann, HJ; + view all
(2017)
Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome.
Blood
, 131
(9)
pp. 974-981.
10.1182/blood-2017-10-810366.
|
Sachchithanantham, S;
Berlanga, O;
Alvi, A;
Mahmood, SA;
Lachmann, HJ;
Gillmore, JD;
Hawkins, PN;
... Wechalekar, AD; + view all
(2017)
Immunoparesis defined by heavy plus light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.
British Journal of Haematology
, 179
(4)
pp. 575-585.
10.1111/bjh.14908.
|
Sachchithanantham, S;
Roussel, M;
Palladini, G;
Klersy, C;
Mahmood, S;
Venner, CP;
Gibbs, S;
... Wechalekar, AD; + view all
(2016)
European Collaborative Study Defining Clinical Profile Outcomes and Novel Prognostic Criteria in Monoclonal Immunoglobulin M-Related Light Chain Amyloidosis.
Journal of Clinical Oncology
, 34
(17)
pp. 2037-2045.
10.1200/JCO.2015.63.3123.
|
Sanchorawala, Vaishali;
Boccadoro, Mario;
Gertz, Morie;
Hegenbart, Ute;
Kastritis, Efstathios;
Landau, Heather;
Mollee, Peter;
... Palladini, Giovanni; + view all
(2021)
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.
Amyloid
, 29
(1)
10.1080/13506129.2021.2002841.
|
Sanchorawala, Vaishali;
Wechalekar, Ashutosh DD;
Kim, Kihyun;
Schönland, Stefan OO;
Landau, Heather JJ;
Kwok, Fiona;
Suzuki, Kenshi;
... Kastritis, Efstathios; + view all
(2023)
Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice.
American Journal of Hematology
10.1002/ajh.26866.
(In press).
|
Saunders, CN;
Chattopadhyay, S;
Huhn, S;
Weinhold, N;
Hoffmann, P;
Noethen, MM;
Joeckel, K-H;
... Hemminki, K; + view all
(2021)
Search for AL amyloidosis risk factors using Mendelian randomization.
Blood Advances
, 5
(13)
pp. 2725-2731.
10.1182/bloodadvances.2021004423.
|
Sethi, S;
Nast, CC;
D'Agati, VD;
Fervenza, FC;
Glassock, RJ;
Stokes, MB;
De Vriese, AS;
... Haas, M; + view all
(2020)
Standardized reporting of monoclonal immunoglobulin-associated renal diseases: recommendations from a Mayo Clinic/Renal Pathology Society Working Group.
Kidney International
, 98
(2)
pp. 310-313.
10.1016/j.kint.2020.03.025.
|
Sharpley, FA;
Manwani, R;
Petrie, A;
Mahmood, S;
Sachchithanantham, S;
Lachmann, HJ;
Martinez De Azcona Naharro, A;
... Wechalekar, AD; + view all
(2021)
Autologous stem cell transplantation vs bortezomib based chemotheraphy for the first‐line treatment of systemic light chain amyloidosis in the UK.
European Journal of Haematology
, 106
(4)
pp. 537-545.
10.1111/ejh.13582.
|
Sharpley, FA;
De-Silva, D;
Mahmood, S;
Sachchithanantham, S;
Ramsay, I;
Garcia Mingo, A;
Worthington, S;
... D Wechalekar, A; + view all
(2020)
Cytomegalovirus reactivation after bortezomib treatment for multiple myeloma and light chain amyloidosis.
European Journal of Haematology
, 104
(3)
pp. 230-235.
10.1111/ejh.13366.
|
Sharpley, FA;
Fontana, M;
Gilbertson, JA;
Gillmore, JD;
Hawkins, PN;
Mahmood, S;
Manwani, R;
... Lachmann, HJ; + view all
(2020)
Amyloidosis Diagnosed in Solid Organ Transplant Recipients.
Transplantation
, 104
(2)
pp. 415-420.
10.1097/TP.0000000000002813.
|
Sharpley, FA;
Fontana, M;
Martinez-Naharro, A;
Manwani, R;
Mahmood, S;
Sachchithanantham, S;
Lachmann, HJ;
... Wechalekar, AD; + view all
(2019)
Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria.
Haematologica
10.3324/haematol.2019.217695.
(In press).
|
Sharpley, FA;
Manwani, R;
Mahmood, S;
Sachchithanantham, S;
Lachmann, H;
Gilmore, J;
Whelan, C;
... Wechalekar, A; + view all
(2018)
Real world outcomes of pomalidomide for treatment of relapsed light chain amyloidosis.
British Journal of Haematology
, 183
(4)
pp. 557-563.
10.1111/bjh.15541.
|
Sharpley, FA;
Manwani, R;
Mahmood, S;
Sachchithanantham, S;
Lachmann, HJ;
Gillmore, JD;
Whelan, CJ;
... Wechalekar, AD; + view all
(2019)
A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis.
Blood Cancer Journal
, 9
, Article 16. 10.1038/s41408-019-0180-1.
|
Sharpley, FA;
Petrie, A;
Mahmood, S;
Sachchithanantham, S;
Lachmann, HJ;
Gillmore, JD;
Whelan, CJ;
... Wechalekar, AD; + view all
(2019)
A 24-year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom.
British Journal of Haematology
, 187
(5)
pp. 642-652.
10.1111/bjh.16143.
|
|
Slart, Riemer HJA;
Chen, Wengen;
Tubben, Alwin;
Tingen, Hendrea SA;
Davies, Daniel R;
Grogan, Martha;
Wechalekar, Ashutosh D;
... Chareonthaitawee, Panithaya; + view all
(2023)
Emerging Role of Scintigraphy Using Bone-Seeking Tracers for Diagnosis of Cardiac Amyloidosis: AJR Expert Panel Narrative Review.
American Journal of Roentgenology
, 222
(1)
, Article e2329347. 10.2214/AJR.23.29347.
|
Suzuki, K;
Wechalekar, AD;
Kim, K;
Shimazaki, C;
Kim, JS;
Ikezoe, T;
Min, CK;
... Lu, J; + view all
(2023)
Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA.
Annals of Hematology
, 102
pp. 863-876.
10.1007/s00277-023-05090-z.
|
Tornatore, L;
Capece, D;
D'Andrea, D;
Begalli, F;
Verzella, D;
Bennett, J;
Acton, G;
... Franzoso, G; + view all
(2019)
Preclinical toxicology and safety pharmacology of the first-in-class GADD45β/MKK7 inhibitor and clinical candidate, DTP3.
Toxicology Reports
, 6
pp. 369-379.
10.1016/j.toxrep.2019.04.006.
|
Vergaro, Giuseppe;
Castiglione, Vincenzo;
Aimo, Alberto;
Prontera, Concetta;
Masotti, Silvia;
Musetti, Veronica;
Nicol, Martin;
... Fontana, Marianna; + view all
(2023)
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis.
European Journal of Heart Failure
, 25
(3)
pp. 335-346.
10.1002/ejhf.2769.
|
Vohra, Sargam Rachit;
Ravichandran, Sriram;
Foard, Darren;
Martinez-Naharro, Ana;
Venneri, Lucia;
Fontana, Marianna;
Whelan, Carol J;
... Wechalekar, Ashutosh D; + view all
(2025)
A retrospective study of isatuximab-pomalidomide-dexamethasone in relapsed/refractory systemic AL amyloidosis.
[Letter].
Haematologica
, 110
(12)
pp. 3109-3113.
10.3324/haematol.2025.287664.
|
Wagner, T;
Page, J;
Burniston, M;
Skillen, A;
Ross, JC;
Manwani, R;
McCool, D;
... Wechalekar, AD; + view all
(2018)
Extracardiac 18F-florbetapir imaging in patients with systemic amyloidosis: more than hearts and minds.
European Journal of Nuclear Medicine and Molecular Imaging
, 45
(7)
pp. 1129-1138.
10.1007/s00259-018-3995-2.
|
Wechalekar, A;
Antoni, G;
Al Azzam, W;
Bergström, M;
Biswas, S;
Chen, C;
Cheriyan, J;
... Falk, RH; + view all
(2022)
Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
BMC Cardiovascular Disorders
, 22
, Article 49. 10.1186/s12872-021-02407-6.
|
Wechalekar, AD;
(2021)
The Evolving Epidemiology of Amyloidosis.
JACC: CardioOncology
, 3
(4)
pp. 534-536.
10.1016/j.jaccao.2021.09.001.
|
Wechalekar, AD;
Chakraborty, R;
Lentzsch, S;
(2020)
Systemic Amyloidosis due to Low-Grade Lymphoma.
Hematology/Oncology Clinics of North America
, 34
(6)
pp. 1027-1039.
10.1016/j.hoc.2020.08.016.
|
Wechalekar, AD;
Sanchorawala, V;
(2022)
Daratumumab in AL amyloidosis.
Blood
, 140
(22)
pp. 2317-2322.
10.1182/blood.2021014613.
|
Wechalekar, Ashutosh D;
Cibeira, M Teresa;
Gibbs, Simon D;
Jaccard, Arnaud;
Kumar, Shaji;
Merlini, Giampaolo;
Palladini, Giovanni;
... Kastritis, Efstathios; + view all
(2022)
Guidelines for non-transplant chemotherapy for treatment of systemic AL amyloidosis: EHA-ISA working group.
Amyloid
10.1080/13506129.2022.2093635.
(In press).
|
Wechalekar, AD;
(2018)
Biomarkers in AL amyloidosis: is the summit in sight?
Blood
, 131
(14)
pp. 1502-1503.
10.1182/blood-2018-02-832113.
|
Wechalekar, AD;
Gillmore, JD;
Wassef, N;
Lachmann, HJ;
Whelan, C;
Hawkins, PN;
(2011)
Abnormal N-terminal fragment of brain natriuretic peptide in patients with light chain amyloidosis without cardiac involvement at presentation is a risk factor for development of cardiac amyloidosis.
Haematologica-Hematology Journal
, 96
(7)
1079- 1080.
10.3324/haematol.2011.040493.
|
Wechalekar, AD;
Whelan, C;
(2017)
Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis.
[Letter].
Blood Cancer Journal
, 7
, Article e546. 10.1038/bcj.2017.26.
|
Wechalekar, K;
Wechalekar, AD;
(2021)
Wild-type transthyretin cardiac amyloidosis: When is a rare disease no longer a rare disease?
Journal of Nuclear Cardiology
, 28
pp. 2857-2859.
10.1007/s12350-020-02275-1.
|
Wisniowski, B;
Wechalekar, A;
(2020)
Confirming the Diagnosis of Amyloidosis.
Acta Haematologica
, 143
(4)
pp. 312-321.
10.1159/000508022.
|
Wong, SW;
Hegenbart, U;
Palladini, G;
Shah, GL;
Landau, HJ;
Warner, M;
Toskic, D;
... Comenzo, RL; + view all
(2018)
Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.
Clinical Lymphoma, Myeloma and Leukemia
, 18
(11)
e493-e499.
10.1016/j.clml.2018.07.292.
|
Ziff, Monica;
Lawson, Gabrielle;
De-Silva, Dunnya;
Cheesman, Simon;
Kyriakou, Charalampia;
Mahmood, Shameem;
Papanikolaou, Xenofon;
... Popat, Rakesh; + view all
(2021)
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.
Leukemia & Lymphoma
, 62
(5)
pp. 1243-1246.
10.1080/10428194.2020.1864356.
|
Conference item
Law, S;
Lachmann, H;
Rezk, T;
Wechalekar, A;
Julian, G;
Motallebzadeh, R;
(2019)
Outcome of Renal Transplantation in Systemic Amyloidosis.
Presented at: 2019 American Transplant Congress, Boston, MA, USA.
|
Law, S;
Lachmann, HJ;
Rezk, T;
Wechalekar, A;
Gillmore, J;
Motallebzadeh, R;
(2019)
Outcome of renal transplantation in systemic amyloidosis.
Presented at: American Transplant Congress 2019, Boston, Massachusetts.
|
Martinez-Naharrro, A;
Kotecha, T;
Baggiano, A;
Boldrini, M;
Rezk, T;
Knight, DS;
Manwani, R;
... Fontana, M; + view all
(2018)
Assessment of Treatment Response in Cardiac AL Amyloidosis Using CMR Mapping - Results at 3 Months, 6 Months and 1 Year Post-Chemotherapy.
Presented at: Imaging and Nuclear Medicine, Session Title: Melvin Judkins Young Investigator Competition.
|